Physician

Erin Chamberlain, M.D.

According to 2025 Medicare claims, Erin Chamberlain, M.D. (NPI: 1902249469) practices hematology/oncology in the San Luis Obispo-Paso Robles, CA market, with the plurality of this provider's patient population coming from San Luis Obispo, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 93401-8054.

Chamberlain's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 794 traditional Medicare patients, billed 209,698 HCPCS/CPT codes, and received $4,741,423 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 867 prescription claims across 209 beneficiaries totaling $1,916,934 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 59 claims. Open Payments data shows 5 records totaling $100. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $31,319 to $4,741,423. Similarly, Part D prescription costs have risen steadily, from $355 to $1,916,934. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	217	368	$31,319
2020	394	34,905	$664,236
2021	388	110,668	$1,851,713
2022	560	178,304	$3,507,482
2023	636	243,310	$4,575,124
2024	794	209,698	$4,741,423

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	18	$355
2016	19	28	$1,158
2017	12	41	$3,358
2018	11	22	$1,898
2019	60	163	$221,650
2020	125	533	$599,508
2021	150	642	$1,110,654
2022	193	1,007	$2,049,190
2023	225	1,200	$2,477,098
2024	209	867	$1,916,934

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	27	$2,333
2021	N/R	N/R	N/R
2022	N/R	13	$693
2023	N/R	59	$6,693
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	199	570	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	375	798	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	231	329	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	363	714	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	172	417	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	25	700	$410,896
Lenvima	Lenvatinib Mesylate	15	450	$342,769
Lenalidomide	Lenalidomide	15	420	$259,263
Promacta	Eltrombopag Olamine	12	360	$86,596
Eliquis	Apixaban	27	1,110	$21,972

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$100	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Erin Chamberlain, M.D.?

Tedicare shows public-source Medicare data for Erin Chamberlain, M.D. (NPI 1902249469), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Erin Chamberlain, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Erin Chamberlain, M.D.?

Erin Chamberlain, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Erin Chamberlain, M.D. have Open Payments data?

Erin Chamberlain, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.